The Petri Dish: Axcella advances long Covid drug


Flagship Pioneering spinout Axcella Therapeutics Inc. has promising results from a small Phase 2a study investigating a drug for long Covid.

Previous 5 Minutes With ... Jamie Dimon, chairman and CEO of JPMorgan Chase & Co.
Next Smokehouse Brewing closing for now, but hopes to reopen